DelveInsight’s, “Treatment Resistant Depression Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the Treatment Resistant Depression pipeline drug profiles, including Treatment Resistant Depression clinical trials and nonclinical stage products. It also covers the Treatment Resistant Depression pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Treatment Resistant Depression Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Treatment Resistant Depression Pipeline landscape @ Treatment Resistant Depression Pipeline Outlook Report
Treatment Resistant Depression Overview
The term “treatment resistant depression” often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized. Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs.
Recent Developmental Activities in the Treatment Resistant Depression Treatment Landscape
For further information, refer to the detailed Treatment Resistant Depression Drugs Launch, Treatment Resistant Depression Developmental Activities, and Treatment Resistant Depression News, click here for Treatment Resistant Depression Ongoing Clinical Trial Analysis
Treatment Resistant Depression Emerging Drugs Analysis
Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as ‘magic mushrooms’. The company has developed a synthesised formulation of psilocybin, COMP 360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. These actions modulate glutamatergic neurotransmission. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor
Treatment Resistant Depression Pipeline Therapeutics Assessment
There are approx. 25+ key companies which are developing the therapies for Treatment Resistant Depression. The companies which have their Treatment Resistant Depression drug candidates in the most advanced stage, i.e. preregistration include, Axsome Therapeutics.
Find out more about the Treatment Resistant Depression Pipeline Segmentation, Therapeutics Assessment, and Treatment Resistant Depression Emerging Drugs @ Treatment Resistant Depression Treatment Landscape
Scope of the Treatment Resistant Depression Pipeline Report
Dive deep into rich insights for drugs for Treatment Resistant Depression Pipeline Companies and Therapies, click here @ Treatment Resistant Depression Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Treatment Resistant Depression Mergers and acquisitions, Treatment Resistant Depression Licensing Activities @ Treatment Resistant Depression Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/